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Abstract
Problem: The purpose of this project was to determine the most effective
prophylactic antibiotic to decrease the number of patients who have urinary tract
infections (UTIs) after pelvic floor reconstructive surgery in a gynecological
reconstructive surgery practice.
Methods: This was a retrospective chart review from 2015-2017 that included 732
subjects from a single practice. All patients underwent pelvic floor reconstructive
surgery, with or without a midurethral sling placed. Patients also had a catheter and
vaginal packing postoperatively. Patients who had a culture-proven UTI within the sixweek postoperative period were noted.
Results: There were less UTIs (χ2 = 12.119, df = 1, P = .000) in the
fluoroquinolone cohort than in the other antibiotic cohort. Additionally, it was found that
there was a statistically significant increase in the prevalence of UTIs in those who had
amoxicillin clavulanic acid (Augmentin) vs. those who had levofloxacin (Levaquin) (χ2 =
13.102, df = 2, P = .001). Vulvovaginal candidiasis reported symptom findings also
proved significant, as the Augmentin cohort had more complaints than any other
antibiotic group (χ2 = 30.010, df = 10, P = .001).
Implications: The project findings reinforced the need for prudence when
considering prophylactic antibiotic use in the postoperative period. While more research
is needed to explore antibiotic treatment options further, the data collected and analyzed
provided novel evidence to guide the decrease of unwanted UTIs in this population. Most
notably, this project proved Augmentin is not the ideal choice for UTI prophylaxis in this
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population because of the high number of proven UTIs found, and the statistically high
prevalence of vulvovaginal candidiasis-related complaints.
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Introduction
Approximately 200,000 women undergo surgery for pelvic floor reconstruction
each year (Boyles, Weber, & Meyn, 2003). Over 10 percent of women are expected to
seek surgical intervention for pelvic floor prolapse or incontinence by the age of 80
(Sutkin, Alperin, Meyn, Wiesenfeld, Ellison, & Zyczynski, 2010). The most common
morbidity associated with pelvic floor reconstructive and incontinence surgery is urinary
tract infections (UTIs) (Sutkin et al., 2010). Pelvic floor reconstructive surgery requires
manipulation of instruments at and near the urethra. While the bladder and urethra are
clean, the vagina and anus are not; all structures are close in proximity, leading to
potential contamination, offering support to the relevance of this topic. Another factor
that impacts UTIs in this population is the risk for incomplete bladder emptying
postoperatively. Whether by denervation of the bladder secondary to a hysterectomy,
postoperative swelling, narcotics and anesthetics, or midurethral sling placement, women
may develop urinary retention, which increases their chances of developing a UTI
(Sutkin et al., 2010).
Lastly, the use of a catheter raises the risk of a UTI postoperatively. Seventy to
eighty percent of complicated UTIs in the United States annually are associated with
indwelling urinary catheters, which accounts for one million UTIs per year (FloresMireles, Walker, Caparon, & Hultgren, 2015). Female patients undergoing pelvic floor
reconstructive surgery may have a catheter placed in surgery that remains indwelling for
several days postoperatively. For this reason, prophylactic antibiotics are often prescribed
to prevent UTI occurrence in the postoperative period (defined as six weeks).
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The purpose of this project was to determine the most effective prophylactic
antibiotic to decrease the number of patients who have UTIs after pelvic floor
reconstructive surgery in a gynecological reconstructive surgery practice. This
retrospective chart review yields data on female pelvic floor reconstructive surgery
patients who have a catheter, and compares effectiveness of prophylactic treatment of
fluoroquinolones versus other antibiotics.
Literature Review
The literature review process relied on several search engines, including Medline,
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane,
PubMed, National Center for Biotechnology Information (NCBI), and EBSCOhost for
pertinent evidence-based research data. The peer-reviewed articles were examined to
support data found. There were many keywords that demonstrated their use in the search
for empirical literature, including UTIs, postoperative complications, pelvic floor
reconstructive surgery, fluoroquinolones, prophylactic use of antibiotics, vaginal surgery,
anti-incontinence surgery, midurethral sling surgery, catheter-associated urinary tract
infections, and antibiotic resistance. The data collected was largely from the past five
years. Limitations in the amount of data found required broadening the search, including
references dating back to 2003.
Inclusion criteria determined for targeting the researched population for this
project include the following: (a) adult, female participants, (b) who have undergone at
least one of the following, cystocele repair with anterior colporrhaphy, rectocele repair
with posterior colporrhaphy, enterocele repair with posterior colporrhaphy, or
sacrospinous colpopexy. Patients must also (c) have a catheter (transurethral catheter or
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suprapubic tube), (d) and vaginal packing. Criterion that exclude potential patients are (a)
those that had any mesh removed at the time of pelvic floor reconstructive surgery, and
(b) those who exclusively had a colpoperineorrhaphy. Patients with prior histories of
recurrent UTIs, those who are postmenopausal, and patients who additionally have a
urethral sling were also noted, as those variables may impact results. All UTIs were
proven by straight cath culture in order to be included in the evidence. Secondary
endpoints that were collected include: self reports of vulvovaginal candidiasis (vaginal
yeast) infections, confirmed clostridium difficile cases, and how many days from surgery
those incidents occurred.
The theoretical framework for this project was based on a model developed by
Marita G. Titler that provides foundation and establishes necessary guidance. Titler
developed the IOWA Model which guided the evidence-based research performed and
supports its use appropriately in practice (Brown, 2014). The steps to this framework are:
(1) determine the issue/problem, (2) decide on a plan, (3) create a team, (4) identify
evidence, (5) analyze the evidence, (6) determine conclusions from the evidence, (7)
navigate change, (8) decide if change is applicable to practice, (9) implement the change,
and (10) disseminate results (Brown, 2014). The need for structure to direct the course of
this project prompted a search for an ideal framework. The IOWA model presents ten
clear elements that propelled the project from inception through completion.
The focused problem for this project is the prevalence of UTIs postoperatively.
Identification of antibiotic effectiveness in preventing UTIs is the second element from
the selected framework. This quality improvement project was conducted by a women’s
health nurse practitioner, with the support of an assembled team that included a
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urogynecologist/gynecological reconstructive surgeon, a doctor of science in
nursing/family nurse practitioner, an OB/GYN resident physician, and a doctor of
philosophy in nursing. A thorough review of literature, collection of data, analysis, and
establishment of conclusions took place prior to determining change implementation, and
circulation of the findings.
Review of the current literature revealed a lack of evidence on the project topic.
In regard to occurrences of postoperative UTIs, data varied substantially. Findings from
extant research in this area are equivocal. There are no consistent conclusive results that
have an answer to the purpose of this project.
According to Mueller et al. (2016), in examining postoperative patients after
pelvic floor reconstructive surgery, an observational study concluded that 66% of
postoperative complications occurred in the first two weeks after surgery and 46% of
those complications were UTIs. The research included a sample size of 396 women; 125
of the women had postoperative complications (Mueller et al., 2016). Guldberg et al.
(2014) studied a larger population of 2,151 women after having surgery for urinary
incontinence, rather than pelvic floor reconstructive surgery. The findings showed that
within the first 60 days postoperatively, 26% of patients who had a history of UTIs
redeemed an antibiotic prescription for a possible UTI (Guldberg et al., 2014). Only 11%
of preoperative non-users of antibiotics to treat UTIs, which was a total of 182 patients,
received a prescription for antibiotics for a possible UTI during the 60 days immediately
following surgery. This evidence supports the plan to note all patients with prior UTIs.
A journal article published in 2008 reviewing relevant randomized controlled
trials (RCTs) evaluated the UTI prevalence after pelvic floor operations. The findings
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from the review of nineteen studies gathered that incidences of UTIs for those receiving
placebos after pelvic floor surgery ranged from 10-64%. (Falagas, Athanasiou, Iavazzo,
Tokas, & Antsaklis, 2008). Alternatively, the UTI occurrence was 0-15% in those who
received cephalosporins, which was identified as being the optimal regimen in UTI
prevention after pelvic floor surgery (Falagas et al., 2008). Falagas et al. (2008) also
concluded rates of UTIs were 13.6% higher in those treated with ampicillin/sulbactam,
27.2% with ciprofloxacin, 10-22.7% with metronidazole, 20% with metronidazole plus
ampicillin, and 28% higher with cotrimoxazole. A study by Swartz et al. (2010), reported
that there was no significant difference in UTI occurrence after midurethral sling surgery
in those who received prophylactic antibiotics (3 days of cephalexin, fluoroquinolone, or
doxycycline), and those who received no antibiotic. Although there was not a urine
culture for every recorded UTI, the results revealed no difference (P = 0.03), except that
there were more low-grade adverse events relating to antibiotic use in those in the
prophylactic antibiotic cohort (Swartz et al., 2010).
While the information accumulated may cause presumptions, it is important to
acknowledge some of the weaknesses in the literature. Many of the studies are examining
different types of surgeries, including generalized pelvic floor surgery, anti-incontinence
surgery, and reconstructive vaginal surgery. All the variations of what surgery was
performed, how it was performed, who performed it and who it was performed on are all
considerations that have significance. Likewise, not all the UTIs reported in the
documentation were confirmed by urine culture. Some of the reported UTIs were based
on self-report and others were assumed from urinalysis for bacteria, nitrates, and
leukocyte esterase. While symptoms such as urinary frequency, urgency, and burning on
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urination may be present, that is not definitive of an infection. Abnormal urinalysis
results can appear as a result of the collection technique and, by controlling these
variables, firm evidence can result. Furthermore, not all patients studied had a catheter, or
had a catheter for at least 7 days.
In this review, antibiotics and their strengths and weaknesses were researched and
observed more closely. A randomized controlled trial assessing nitrofurantoin (Macrobid)
prophylaxis in catheterized patients after pelvic reconstructive surgery with 159
participants concluded that prophylactic Macrobid daily does not reduce the risk for
postoperative UTIs (Dieter et al., 2014). Dieter et al. (2014) looked at the three weeks
immediately following surgery; results indicated 22% of the 81 patients receiving
Macrobid and 13% of the 78 patients given the placebo had UTIs, either suspected or
culture-proven. Conversely, Jackson et al., (2013) found that a three-day course of
prophylactic Macrobid after surgery for midurethral sling placement was significant (P =
.04) to decrease postoperative UTIs. The randomized, double-blinded, placebocontrolled, multicenter trial enrolled 149 subjects and measured UTI prevalence by
meeting certain symptomatology; UTIs were not culture-proven (Jackson et al., 2013).
Moreover, another study looked at 449 subjects, 211 randomized to Macrobid, and 224
randomized to placebo, after pelvic organ prolapse and/or urinary incontinence surgery
with suprapubic catheterization (Rogers et al., 2004). Findings included a significant
decrease in culture-proven UTIs in those who received Macrobid (P = 0.002) at the time
of suprapubic tube removal, but not at the 6-8-week postoperative check-up (Rogers et
al., 2004).
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Sutkin et al. (2010) concluded that prolonged duration of catheterization (>10
days after surgery) is significant to cause UTIs, despite antibiotic prophylaxis. In a
retrospective chart review of 394 women who had undergone surgery for pelvic floor
prolapse or stress incontinence, it was found that there was a significantly higher
prevalence of UTIs in the six-week postoperative period the longer there was a catheter
in, or clean intermittent self-catheterization (CSIC) was practiced (Sutkin et al., 2010).
While many limitations have been acknowledged, there are also strengths present.
By recognizing sensitivities, a better understanding of the functioning of antibiotics can
be assessed to provide sufficient prophylactic outcomes for patients. The data collected
has suggested that postoperative complications, including UTIs, will likely materialize
shortly after surgery, rather than weeks out; this evidence can be compared to future data
collection to determine relevance. With the nature of pelvic floor reconstructive surgery,
the anatomical location of the urethra and its adjacency to other contaminated structures
pose increased risk to the patients’ likelihood of developing a UTI.
Methods
The purpose for this project is based on the postulate that comparing
postoperative antibiotic effectiveness will result in action to reduce the number of
postoperative UTIs. The approach was a retrospective design that, by utilizing evidencebased practice and data collection, has the potential to implement change. The goal of
achieving the greatest outcome for the population researched, with the least amount of
adverse effects possible, is of highest priority. The setting for the project was a healthcare
facility in Saint Louis, Missouri. Approximately two years of data collectively was
synthesized from a convenience sample of 732 female patients who underwent pelvic
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floor reconstructive surgery in the years 2015 through 2017. All patients included had
pelvic floor reconstructive surgery, and also may or may not have a midurethral sling
placed for stress urinary incontinence. Patients also had a temporary catheter
(transurethral or suprapubic) and vaginal packing postoperatively. Patients that have
additionally undergone any type of mesh removal, and those having only a
colpoperineorrhaphy, were not included in the dataset.
Institutional Review Board training for the facility setting and for the University
of Missouri Saint Louis was obtained. Data collection occurred from the electronic health
records (EHR) system as a retrospective medical record review; every patient was
assigned a number to de-identify personal information. A master log with patient names
and assigned numbers was protected and maintained at the healthcare facility. Data
collected included: age of subject at time of surgery, type of reconstructive surgery the
subject underwent, postoperative antibiotic prescribed, length of time the catheter was in,
if they had a proven UTI infection during the postoperative period, how many days after
surgery the UTI occurred, the bacteria responsible for the UTI, the antibiotics resistance
and susceptibility, if the patient is postmenopausal, if the patient has a prior history of
UTIs, and if the patient has a urethral sling. All data collected was compiled on a
spreadsheet for analysis. The data was then converted into an SPSS spreadsheet and tests
including frequencies and chi-squares were performed to analyze the information.
Results
Several outcomes were identified through this process. When comparing
effectiveness of antibiotics for UTI prophylaxis, it became clear that certain antibiotics
were more adequate. Out of 732 patients, 315 took a fluoroquinolone (Levaquin = 312;
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Ciprofloxacin = 3), 414 took either Augmentin (n = 326), Bactrim (n = 38), or Macrobid
(n = 50), and 3 subjects received no antibiotic. Only 4 subjects who took a
fluoroquinolone got a UTI. Twenty-seven subjects got a UTI after taking one of the other
antibiotics; this finding was statistically significant (χ2 = 12.119, df = 1, P = .000).
Augmentin users had the highest prevalence of postoperative UTIs (n = 23). This finding
was also statistically significant at χ2 = 11.378, df = 1, P = 0.001. When then comparing
Augmentin to those taking fluoroquinolones, the same significant result was found. After
breaking down the analysis to the two largest antibiotic groups prescribed in the practice,
further outcomes were explored between the Augmentin and Levaquin cohorts (see
Appendix A). The Levaquin users (n = 312) had 4 UTIs and the Augmentin users (n =
326) had 23 UTIs. This finding was statistically significant (χ2 = 13.102, df = 2, P =
.001). Further examination of the demographics of the Levaquin and Augmentin cohorts
can be found in Appendix A.
Other parallels explored included examining the possible correlation between
proven UTIs and postmenopausal status, prior history of UTIs, having a current midurethral sling, having a hysterectomy as part of their surgery, and the length of time the
catheter was in. Of note, there was significance in those with prior histories of UTIs,
those with a mid-urethral sling, and those with a catheter in longer than 10 days (see
Appendix B). When considering the length of time the catheter was in, only 11 UTIs
occurred within 10 days of surgery, whereas 20 UTIs were confirmed in those who had
the catheter longer than 10 days. Of the 31 UTIs identified, Escherichia coli was the
responsible bacteria for 10 of the infections (32.3%). Then, after acknowledging the most
frequent UTI-causing bacteria, it led to the analysis of the most resistant and susceptible
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antibiotic choices for the UTIs. The three antibiotics that the 31 infections were most
frequently susceptible to were Tobramycin (n = 28), Gentamicin (n = 29), and Cefepime
(n = 26). Of the antibiotics that were prescribed postoperatively, here is the bacteria
susceptible[s] vs. resistant[r] breakdown: Levaquin (n = 24[s]/2[r]), Augmentin (n =
15[s]/3[r]), Bactrim (n = 17[s]/5[r]), Macrobid (n = 21[s]/2[r]), and Ciprofloxacin (n =
23[s]/5[r]). Conversely, the antibiotics with the highest frequency of resistance were
Ampicillin (n = 12) and Tetracycline (n = 7).
Lastly, the self-reports of vulvovaginal candidiasis infections requiring medicinal
treatment and the incidents of clostridium difficile were investigated. Of the population
researched, there were no confirmed cases of clostridium difficile. There were however
48 subjects treated for a vulvovaginal candidiasis infection. Of the 48 yeast episodes,
there was a statistical finding of χ2 = 30.010, df = 10, P = .001 of those who had taken
Augmentin postoperatively (see Appendix D).
Discussion
The findings from this study suggested that fluoroquinolone use for the
prophylactic treatment of UTIs is superior to other antibiotics. More specifically,
Levaquin is a preferred treatment, in regard to the prevention of UTIs and shows a fairly
small risk for vulvovaginal candidiasis infections, when compared to Augmentin.
Although other antibiotics were included, as well as 3 subjects that received no antibiotic,
the proportion of subjects given Augmentin and Levaquin was far greater. Then,
comparing those two cohorts, we must take into consideration the potential differences in
the populations that could contribute to these findings. When matching the populations
side-by-side, it was evident only few differences were found.
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When considering the implications these results have on practice, it is important
to weigh the risks vs benefits of the antibiotic options. While Levaquin had a
significantly lower rate of postoperative UTIs, it does have a black box warning for
tendon rupture (Tanne, 2008). Evidence from this study points to the superiority of
Levaquin, but other risks must be calculated when prescribing is considered. Augmentin
was identified as having a poor ability to prevent UTIs and a high incidence of
vulvovaginal candidiasis complaints, leading to the inference that it may not be the ideal
postoperative treatment of choice either. It would be beneficial to conduct future research
comparing the Bactrim and Macrobid more closely, because this project had limited
patients on these antibiotics. However, from the narrow cohorts investigated, the
drawbacks seemed low.
Conclusion
This project demonstrated that there are both advantages and disadvantages to
varying antibiotics in the postoperative period. In order to establish the greatest care for
this patient population, clinicians must place emphasis on the preventative abilities of
individual antibiotics relating to UTIs, as well as the negative effects of each medication.
The evidence needs to be compiled and considered when making changes or maintaining
current treatment regimens. This study showed a large difference in the prevention
capabilities between Levaquin and Augmentin, but data was limited on Ciprofloxacin,
Macrobid, and Bactrim. While acknowledging the robust data from the fluoroquinolone
class, it must also be noted that this is not the only data to consider when prescribing a
prophylactic antibiotic to a patient. The black box warning, however rare, is cautionary
and must also be weighed when choosing the proper treatment for an individual.
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The findings support the need to amend the prescribing patterns to avoid
Augmentin and consider more frequent prescribing of Bactrim and Macrobid.
Discriminating amongst the high and low risk factors to prevent postoperative UTIs in
this population is also key. It would be appropriate to consider using Levaquin in
populations found to be at a higher risk for a postoperative UTI, including those with a
prior history of UTIs and those who plan to have a midurethral sling/suprapubic tube
placed for stress urinary incontinence.
Ultimately, much light was shed on the pitfalls of some antibiotic choices, most
notably Augmentin, and leads to the need for further research to identify the optimal
choice for UTI prevention in the pelvic floor reconstructive surgical patient.
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Appendices
Appendix A
Fluoroquinolones vs. Other Antibiotics - Cohort Comparison
Variables

Fluoroquinolones

Other Antibiotic

P-Value

Postmenopausal

243/315 (77.1%)

312/414 (75.4%)

.576

Midurethral Sling/SPT

153/315 (48.6%)

186/414 (44.9%)

.326

Hysterectomy

157/315 (49.8%)

204/414 (49.3%)

.880

History of UTIs

78/315 (24.8%)

108/414 (26.1%)

.684

Catheter >10 days

93/315 (29.5%)

111/414 (26.8%)

.419

The p-value was set to <.05.

Levaquin vs. Augmentin - Proven UTI Crosstabulation
Proven UTI

Antibiotic

Total

Yes

No

Other

4

90

94

Levaquin

4

308

312

Augmentin

23

303

326

Total

31

701

732

Chi-Square Tests - Levaquin vs. Augmentin
Value

df

Asymptotic Significance (2-sided)

Pearson Chi-Square

13.102a

2

.001

Likelihood Ratio

14.512

2

.001

Number of Valid Cases

732
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Levaquin vs. Augmentin - Cohort Comparison
Variables

Levaquin

Augmentin

P-Value

Postmenopausal

240/312 (76.9%)

243/326 (74.5%)

.716

Midurethral Sling/SPT

151/312 (48.4%)

141/326 (43.3%)

.270

Hysterectomy

157/312 (50.3%)

162/326 (49.7%)

.734

History of UTIs

76/312 (24.4%)

75/326 (23.0%)

.009*

Catheter >10 days

93/312 (29.8%)

78/326 (23.9%)

.030*

These are individual chi-squares.
The p-value was set to <.05. *Denotes significant finding

Appendix B
Association of UTIs with Postoperative Antibiotics and Other Factors
Variable

Chi-Square

P-Value

Prior History of UTIs (n = 17)

14.603

< .0001*

Catheter in Longer than 10 days (n = 20)

21.402

< .0001*

Current Midurethral Sling (n = 22)

7.824

.005*

Post-op Antibiotic = Augmentin (n = 23)

11.378

.001*

Postmenopausal (n = 25)

.390

.532

Surgery Included a Hysterectomy (n = 15)

.019

.891

These are individual chi-squares. The df was 1 for each of these crosstabulations.
The p-value was set to <.05. *Denotes significant finding
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Appendix C
Transurethral vs. Suprapubic - Cohort Comparison
Variable

Transurethral
n = 392 (53.6%)

Suprapubic
N = 340 (46.4%)

P-Value

Age (Years)

61 (29-86)

59 (28-85)

.466

Postmenopausal

307/392 (78.3%)

249/340 (73.2%)

.109

Prior history of UTIs

100/392 (25.5%)

87/340 (25.6%)

.981

Incidence of UTIs

9/392 (2.3%)

22/340 (6.5%)

.005*

Catheter > 10 days

2/392 (0.5%)

203/340 (59.7%)

< .0001*

These are individual chi-squares.
The p-value was set to <.05. *Denotes significant finding
Appendix D
Vulvovaginal Candidiasis Crosstabulation
Vaginal Yeast Infection
Total

Postoperative Antibiotic

Yes

No

Levaquin

7

305

312

Augmentin

39

287

326

Bactrim

0

38

38

Ciprofloxacin

0

3

3

Macrobid

2

48

50

Total

48

684

732

Chi-Square Tests - Vulvovaginal Candidiasis Infections

Pearson Chi-Square

Value

df

Asymptotic Significance (2-sided)

30.010a

10

.001

a. 12 cells (66.7%) have expected count less than 5. The minimum expected count is .00.

